为全球首个猫咪液体活检癌症检测测试铺平道路
, /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) (&#34;Volition&#34;), 一家跨国表观遗传学公司，宣布了一项临床研究结果，显示其 Nu.Q® Vet Feline 检测在检测猫淋巴瘤方面具有高准确性，这是该物种中最常见的癌症 1。在 100% 的特异性下，即没有假阳性，该检测检测到了超过 80% 的猫淋巴瘤 2。这一突破标志着我们期待开发出全球首个简单、经济的基于血液的猫癌液体活检测试，这在兽医学中是一个重要的未满足需求。
Frédéric Wuilque, Volition 全球产品副总裁评论道：
&#34;历史上，猫的癌症早期诊断一直非常困难，通常需要在症状已经进展后进行侵入性活检或昂贵的影像学检查。兽医们多年来一直在寻求猫咪解决方案。&#34;
&#34;我们的使命是使癌症筛查成为每只宠物年度健康检查的常规部分，在成功国际推广我们的犬类癌症检测后，我们现在证明了我们的技术对猫也有效。&#34;
&#34;我们期待完成产品开发，并通过我们现有的分销网络，包括参考实验室和现场检测平台，使 Nu.Q® Vet Feline 测试可用。&#34;
Nu.Q® Vet Feline 测试进入了一个重要的、快速增长的市场：
<ul>
<li>庞大的人口： 美国仅有约 7380 万只宠物猫3。</li>
<li>高风险： 估计约 每 5 只猫中就有 1 只 会在其一生中患上癌症 4。猫淋巴瘤是该物种中最常见的癌症，是 Nu.Q® 检测的主要目标。</li>
<li>“老年” 群体： 超过 25% 的美国猫 被认为是老年猫（8 岁及以上）5，代表着每年超过 1800 万只宠物的定期筛查机会 3,5。</li>
<li>市场增长： 北美兽医肿瘤学市场预计到 2025 年将达到 17.7 亿美元，其中猫类细分市场预计将以比犬类细分市场更快的复合年增长率增长，原因是主人意识的提高和对猫特定治疗的关注增加&#34;6。</li>
</ul>
Gael Forterre, Volition 首席商业官评论道：
&#34;这代表了 Volition 的一个巨大的商业机会：
<ul>
<li>这项研究在同行评审期刊上的发表预计将随后解锁 500 万美元的合同里程碑付款。</li>
<li>我们还将在这个庞大且不断增长的市场中产生持续的收入，因为我们的技术满足了未满足的需求。</li>
</ul>
&#34;Nu.Q® Vet Canine 测试已经在 20 多个国家可用，我们相信增加一个猫咪等效产品可能会使我们在伴侣动物领域的总可寻址市场翻倍。&#34;
<ol>
<li>Vail D, Thamm D, Liptak J, eds. Withrow and MacEwen's Small Animal Clinical Oncology. 第 6 版. Elsevier Health Sciences; 2019。</li>
<li>数据存档，Volition</li>
<li>AVMA 宠物拥有权来源书 (2025) 6 APPA 全国宠物主人调查 (2025)</li>
<li>猫会得癌症吗？了解猫癌症如淋巴瘤和 SCC。Imprimed</li>
<li>数据存档，Volition TAM 模型</li>
<li>朝向医疗保健：兽医肿瘤市场洞察 (2025 年 10 月)</li>
</ol>
关于 Volition
关于 Volition：Volition 是一家专注于推进表观遗传学科学的跨国公司。Volition 致力于通过早期检测以及疾病和治疗监测来拯救生命并改善人类和动物在重大疾病中的预后。
通过其子公司，Volition 正在开发和商业化简单、易用、经济实惠的血液检测，以帮助检测和监测一系列疾病，包括一些癌症和与 NETosis 相关的疾病，如脓毒症。早期检测和监测不仅有潜力延长患者的生命，还能改善他们的生活质量。
Volition 的研发活动集中在比利时，在美国设有创新实验室和办公室，并在伦敦设有办公室。
在 Volition 网站地址中找到的内容不应被视为本文件的一部分，也不应被视为本文件的引用。该网站地址仅作为非活动文本引用包含在本文件中。
媒体咨询： Louise Batchelor, Volition, mediarelations@volition.com +44 (0) 7557 774620
投资者关系： Jeremy Feffer, LifeSci Advisors, jfeffer@lifesciadvisors.com +1-212-915-2568
安全港声明
本新闻稿或相关视频或链接中的声明可能是根据《1933 年证券法》第 27A 条及《1934 年证券交易法》第 21E 条的定义的 “前瞻性声明”，涉及可能导致实际结果与前瞻性声明中预期或预测的结果存在重大差异的风险和不确定性。诸如 “预计”、“预期”、“打算”、“计划”、“目标”、“瞄准”、“相信”、“寻求”、“估计”、“优化”、“潜力”、“目标”、“建议”、“可能”、“将”、“应该”、“或许”、“会” 等类似表达识别出前瞻性声明。这些前瞻性声明涉及的主题包括，Volition 对收入机会和增长的预期、Volition 的血液基础诊断、预后和疾病监测测试的有效性和可用性、Volition 开发和成功商业化这些测试平台以早期检测癌症和其他疾病的能力，以及作为这些疾病的诊断、预后或监测工具的能力、Volition 对未来出版物的预期、Volition 在与第三方为其产品达成许可和/或分销协议方面的成功，以及 Volition 对这些协议条款的预期。由于众多风险和不确定性，Volition 的实际结果可能与这些前瞻性声明中所指示的结果存在重大差异，包括但不限于测试有效性研究的结果。例如，如果 Volition 未能开发和商业化诊断、预后或疾病监测产品，可能无法执行其运营计划。其他风险和不确定性包括 Volition 未能获得必要的监管许可或批准以分销和营销未来产品；市场未能接受 Volition 开发管道中的产品或 Volition 可能开发的任何其他诊断、预后或疾病监测产品；Volition 未能获得足够的知识产权保护；Volition 将面临激烈的竞争，且由于诊断和疾病监测市场的高度竞争性及其快速技术变革，Volition 计划的产品可能会变得过时；国内和国际经济的下滑；以及其他风险，包括在 Volition 最近的 10-K 表格年度报告和 10-Q 表格季度报告中识别的风险，以及 Volition 向证券交易委员会提交的其他文件。这些声明基于当前的预期、估计和关于 Volition 业务的预测，部分基于管理层做出的假设。这些声明并不保证未来的表现，并涉及难以预测的风险、不确定性和假设。前瞻性声明是在本发布之日作出的，除法律要求外，Volition 不承担更新其前瞻性声明以反映未来事件或情况的义务。
Nucleosomics™、Capture-PCR™、Capture-Seq™和 Nu.Q®及其各自的标志是 VolitionRx Limited 及其子公司的商标和/或服务标志。本新闻稿或相关视频或链接中提到的所有其他商标、服务标志和商号均为其各自所有者的财产。此外，除非另有说明，所有提到的 “$” 均指美国法定货币。
来源：VolitionRx Limited

VNRX

VolitionRx Limited（纽约证券交易所代码：VNRX）宣布其 Nu.Q® Vet Feline 检测的突破性临床数据，在检测猫淋巴瘤方面实现了 100% 的特异性，检测准确率超过 80%。这标志着全球首个可负担的基于血液的猫癌症液体活检测试的潜在推出，满足了兽医学中的重大需求。北美兽医肿瘤市场预计将增长，Volition 旨在抓住这一机会。Nu.Q® Vet Canine 测试已在 20 多个国家提供，而猫测试可能使其市场覆盖范围翻倍

Paves the Way for World's First Feline Liquid Biopsy Test for Cancer Detection
<div class="lb-trans">为全球首个猫咪液体活检癌症检测测试铺平道路
</div>, /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) (&#34;Volition&#34;), a multi-national epigenetics company, announces results from a clinical study demonstrating the high accuracy of its Nu.Q® Vet Feline assay in detecting lymphoma in cats, the most common cancer in the species1. At 100% specificity, i.e. no false positives, the assay detected over 80% of feline lymphomas2 . This breakthrough marks the development of what we expect to be the world's first simple, affordable blood-based liquid biopsy test for feline cancer, a significant unmet need in veterinary medicine.
<div class="lb-trans">, /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) (&#34;Volition&#34;), 一家跨国表观遗传学公司，宣布了一项临床研究结果，显示其 Nu.Q® Vet Feline 检测在检测猫淋巴瘤方面具有高准确性，这是该物种中最常见的癌症 1。在 100% 的特异性下，即没有假阳性，该检测检测到了超过 80% 的猫淋巴瘤 2。这一突破标志着我们期待开发出全球首个简单、经济的基于血液的猫癌液体活检测试，这在兽医学中是一个重要的未满足需求。
</div>Frédéric Wuilque, VP-Global Products, Volition commented :
<div class="lb-trans">Frédéric Wuilque, Volition 全球产品副总裁评论道：
</div>&#34;Historically, cancer in cats has been notoriously difficult to diagnose early, often requiring invasive biopsies or expensive imaging after symptoms have already progressed. Veterinarians have been asking for a feline solution for years.
<div class="lb-trans">&#34;历史上，猫的癌症早期诊断一直非常困难，通常需要在症状已经进展后进行侵入性活检或昂贵的影像学检查。兽医们多年来一直在寻求猫咪解决方案。&#34;
</div>&#34;Our mission is to make cancer screening a routine part of every pet's annual wellness check and following the successful international rollout of our canine cancer test, we have now demonstrated that our technology is also effective for cats.
<div class="lb-trans">&#34;我们的使命是使癌症筛查成为每只宠物年度健康检查的常规部分，在成功国际推广我们的犬类癌症检测后，我们现在证明了我们的技术对猫也有效。&#34;
</div>&#34;We look forward to completing product development and making the Nu.Q® Vet Feline Test available through our existing distribution networks including reference laboratories and point-of-care platforms.&#34;
<div class="lb-trans">&#34;我们期待完成产品开发，并通过我们现有的分销网络，包括参考实验室和现场检测平台，使 Nu.Q® Vet Feline 测试可用。&#34;
</div>The Nu.Q® Vet Feline Test taps into a significant, rapidly growing market:
<div class="lb-trans">Nu.Q® Vet Feline 测试进入了一个重要的、快速增长的市场：
</div><ul>
<li>Large Population: There are approximately 73.8 million pet cats in the United States alone3.</li>
<li>High Risk: It is estimated that approximately 1 in 5 cats will develop cancer in their lifetime4. Feline lymphoma, the most common cancer in the species, is a primary target for the Nu.Q® assay.</li>
<li>The &#34;Senior&#34; Segment: Over 25% of U.S. cats are considered seniors (aged 8+) 5, representing a recurring annual screening opportunity for over 18 million pets in the U.S.3,5</li>
<li>Market Growth: The North American veterinary oncology market is projected to reach $1.77 billion by 2025, with the feline segment expected to grow at a faster Compound Annual Growth Rate than the canine segment due to increasing owner awareness and a growing focus on feline-specific treatments&#34;6.</li>
</ul>
<div class="lb-trans"><ul>
<li>庞大的人口： 美国仅有约 7380 万只宠物猫3。</li>
<li>高风险： 估计约 每 5 只猫中就有 1 只 会在其一生中患上癌症 4。猫淋巴瘤是该物种中最常见的癌症，是 Nu.Q® 检测的主要目标。</li>
<li>“老年” 群体： 超过 25% 的美国猫 被认为是老年猫（8 岁及以上）5，代表着每年超过 1800 万只宠物的定期筛查机会 3,5。</li>
<li>市场增长： 北美兽医肿瘤学市场预计到 2025 年将达到 17.7 亿美元，其中猫类细分市场预计将以比犬类细分市场更快的复合年增长率增长，原因是主人意识的提高和对猫特定治疗的关注增加&#34;6。</li>
</ul>
</div>Gael Forterre, Chief Commercial Officer, Volition commented:
<div class="lb-trans">Gael Forterre, Volition 首席商业官评论道：
</div>&#34;This represents a tremendous commercial opportunity for Volition:
<div class="lb-trans">&#34;这代表了 Volition 的一个巨大的商业机会：
</div><ul>
<li>the publication of this study in a peer reviewed journal is expected subsequently to unlock a $5 million contractual milestone payment.</li>
<li>we will also generate ongoing revenue, in this large and growing market where our technology meets an unmet need</li>
</ul>
<div class="lb-trans"><ul>
<li>这项研究在同行评审期刊上的发表预计将随后解锁 500 万美元的合同里程碑付款。</li>
<li>我们还将在这个庞大且不断增长的市场中产生持续的收入，因为我们的技术满足了未满足的需求。</li>
</ul>
</div>&#34;The Nu.Q® Vet Canine test is already available in more than 20 countries, and we believe the addition of a feline equivalent could potentially double our total addressable market in the companion animal space.&#34;
<div class="lb-trans">&#34;Nu.Q® Vet Canine 测试已经在 20 多个国家可用，我们相信增加一个猫咪等效产品可能会使我们在伴侣动物领域的总可寻址市场翻倍。&#34;
</div><ol>
<li>Vail D, Thamm D, Liptak J, eds. Withrow and MacEwen's Small Animal Clinical Oncology. 6th ed. Elsevier Health Sciences; 2019.</li>
<li>Data on file, Volition</li>
<li>AVMA Pet Ownership Sourcebook (2025) &amp; APPA National Pet Owners Survey (2025)</li>
<li>Can Cats Get Cancer? Understanding Feline Cancers Like Lymphoma &amp; SCC. Imprimed</li>
<li>Data on file, Volition TAM model</li>
<li>Towards Healthcare: Veterinary Oncology Market Insights (October 2025)</li>
</ol>
<div class="lb-trans"><ol>
<li>Vail D, Thamm D, Liptak J, eds. Withrow and MacEwen's Small Animal Clinical Oncology. 第 6 版. Elsevier Health Sciences; 2019。</li>
<li>数据存档，Volition</li>
<li>AVMA 宠物拥有权来源书 (2025) 6 APPA 全国宠物主人调查 (2025)</li>
<li>猫会得癌症吗？了解猫癌症如淋巴瘤和 SCC。Imprimed</li>
<li>数据存档，Volition TAM 模型</li>
<li>朝向医疗保健：兽医肿瘤市场洞察 (2025 年 10 月)</li>
</ol>
</div>About Volition
<div class="lb-trans">关于 Volition
</div>About Volition: Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.
<div class="lb-trans">关于 Volition：Volition 是一家专注于推进表观遗传学科学的跨国公司。Volition 致力于通过早期检测以及疾病和治疗监测来拯救生命并改善人类和动物在重大疾病中的预后。
</div>Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential not only to prolong the life of patients, but also to improve their quality of life.
<div class="lb-trans">通过其子公司，Volition 正在开发和商业化简单、易用、经济实惠的血液检测，以帮助检测和监测一系列疾病，包括一些癌症和与 NETosis 相关的疾病，如脓毒症。早期检测和监测不仅有潜力延长患者的生命，还能改善他们的生活质量。
</div>Volition's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London.
<div class="lb-trans">Volition 的研发活动集中在比利时，在美国设有创新实验室和办公室，并在伦敦设有办公室。
</div>The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only.
<div class="lb-trans">在 Volition 网站地址中找到的内容不应被视为本文件的一部分，也不应被视为本文件的引用。该网站地址仅作为非活动文本引用包含在本文件中。
</div>Media Enquiries: Louise Batchelor, Volition, mediarelations@volition.com +44 (0) 7557 774620
<div class="lb-trans">媒体咨询： Louise Batchelor, Volition, mediarelations@volition.com +44 (0) 7557 774620
</div>Investor Relations: Jeremy Feffer, LifeSci Advisors, jfeffer@lifesciadvisors.com +1-212-915-2568
<div class="lb-trans">投资者关系： Jeremy Feffer, LifeSci Advisors, jfeffer@lifesciadvisors.com +1-212-915-2568
</div>Safe Harbor Statement
<div class="lb-trans">安全港声明
</div>Statements in this press release or associated video or link may be &#34;forward-looking statements&#34; within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as &#34;expects,&#34; &#34;anticipates,&#34; &#34;intends,&#34; &#34;plans,&#34; &#34;aims,&#34; &#34;targets,&#34; &#34;believes,&#34; &#34;seeks,&#34; &#34;estimates,&#34; &#34;optimizing,&#34; &#34;potential,&#34; &#34;goal,&#34; &#34;suggests,&#34; &#34;could,&#34; &#34;would,&#34; &#34;should,&#34; &#34;may,&#34; &#34;will&#34; and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other topics, Volition's expectations related to revenue opportunities and growth, the effectiveness and availability of Volition's blood-based diagnostic, prognostic and disease monitoring tests, Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer and other diseases as well as serving as a diagnostic, prognostic or disease monitoring tools for such diseases, Volition's expectations regarding future publications, Volition's success in securing licensing and/or distribution agreements with third parties for its products, and Volition's expectations regarding the terms of such agreements. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic, prognostic or disease monitoring products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic, prognostic or disease monitoring products Volition might develop; Volition's failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics and disease monitoring market and its rapid technological change; downturns in domestic and foreign economies; and other risks, including those identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.
<div class="lb-trans">本新闻稿或相关视频或链接中的声明可能是根据《1933 年证券法》第 27A 条及《1934 年证券交易法》第 21E 条的定义的 “前瞻性声明”，涉及可能导致实际结果与前瞻性声明中预期或预测的结果存在重大差异的风险和不确定性。诸如 “预计”、“预期”、“打算”、“计划”、“目标”、“瞄准”、“相信”、“寻求”、“估计”、“优化”、“潜力”、“目标”、“建议”、“可能”、“将”、“应该”、“或许”、“会” 等类似表达识别出前瞻性声明。这些前瞻性声明涉及的主题包括，Volition 对收入机会和增长的预期、Volition 的血液基础诊断、预后和疾病监测测试的有效性和可用性、Volition 开发和成功商业化这些测试平台以早期检测癌症和其他疾病的能力，以及作为这些疾病的诊断、预后或监测工具的能力、Volition 对未来出版物的预期、Volition 在与第三方为其产品达成许可和/或分销协议方面的成功，以及 Volition 对这些协议条款的预期。由于众多风险和不确定性，Volition 的实际结果可能与这些前瞻性声明中所指示的结果存在重大差异，包括但不限于测试有效性研究的结果。例如，如果 Volition 未能开发和商业化诊断、预后或疾病监测产品，可能无法执行其运营计划。其他风险和不确定性包括 Volition 未能获得必要的监管许可或批准以分销和营销未来产品；市场未能接受 Volition 开发管道中的产品或 Volition 可能开发的任何其他诊断、预后或疾病监测产品；Volition 未能获得足够的知识产权保护；Volition 将面临激烈的竞争，且由于诊断和疾病监测市场的高度竞争性及其快速技术变革，Volition 计划的产品可能会变得过时；国内和国际经济的下滑；以及其他风险，包括在 Volition 最近的 10-K 表格年度报告和 10-Q 表格季度报告中识别的风险，以及 Volition 向证券交易委员会提交的其他文件。这些声明基于当前的预期、估计和关于 Volition 业务的预测，部分基于管理层做出的假设。这些声明并不保证未来的表现，并涉及难以预测的风险、不确定性和假设。前瞻性声明是在本发布之日作出的，除法律要求外，Volition 不承担更新其前瞻性声明以反映未来事件或情况的义务。
</div>Nucleosomics™, Capture-PCR™, Capture-Seq™ and Nu.Q® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release or associated video or link are the property of their respective owners. Additionally, unless otherwise specified, all references to &#34;$&#34; refer to the legal currency of the United
<div class="lb-trans">Nucleosomics™、Capture-PCR™、Capture-Seq™和 Nu.Q®及其各自的标志是 VolitionRx Limited 及其子公司的商标和/或服务标志。本新闻稿或相关视频或链接中提到的所有其他商标、服务标志和商号均为其各自所有者的财产。此外，除非另有说明，所有提到的 “$” 均指美国法定货币。
</div>SOURCE VolitionRx Limited
<div class="lb-trans">来源：VolitionRx Limited
</div>

VolitionRx 宣布 Nu.Q®兽医癌症测试在猫中的突破性临床数据 | VNRX 股票新闻